R1 Therapeutics
Last verified 2026-06-14. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $77.5Mattributed |
|---|---|
| Latest round | series-a, $77.5M, 2026-03-17attributed |
| Founded | 2022 |
| Headquarters | Boston |
| Industry | healthcare |
| Stage | series-a |
| Website | r1therapeutics.com |
R1 Therapeutics develops AP306, a first-in-class pan phosphate-transporter inhibitor that blocks GI phosphate absorption to treat hyperphosphatemia in chronic kidney disease. It targets CKD patients on dialysis or post-transplant. Active-transporter blockade replaces 9-15 binder pills a day, backed by a $77.5M Series A led by DaVita Venture Group.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-03-17 | series-a | $77.5M | undisclosed |
Detected tech stack
cloudflare, cloudflare bot management, hsts, react, remix, styled-components, web-vitals
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series A, $77.5M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $77.5M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | r1therapeutics.com, read 2026-06-14 |
| Description | self-reported | r1therapeutics.com, read 2026-06-14 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.